

Paper # 12

(Modified) PTO/SB/08A-B (10-96) Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)


Complete if Known						
Application Number 09/648,569						
Filing Date	August 25, 2000					
First Named Inventor	Anders, Hjelholt Pedersen					
Group Art Unit	1633_ 1647					
Examiner Name	Unassigned J. Schova Seyon					
Attorney Docket Number	31-107600US					

				Ü.	S. PATENT DOCUMENTS	<u> </u>	
	Examiner Initials		U.S. Patent Do Number		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
5	S	AA	4,588,585		Mark et al.	05-13-1986	/
		AB	4,686,191		Itoh et al.	08-11-1987	
		AC	4,769,233		Bell et al.	09-06-1988	
		AD	4,904,584		Shaw	02-27-1990	
		ΑE	4,914,033		Bell et al.	04-03-1990	
\Box		AF	4,917,888		Katre et al.	04-17-1990	
		AG	4,966,843		McCormick et al.	10-30-1990	
7		АН	5,218,092		Sasaki et al. 06	08-06-1993	
		ΑI	5,376,567		McCormick et al.	12-27-1994	
15		AJ	5,382,657		McCormick et al. KnAns i EN 127 e + a Heffmann-La-Roche Inc.	01-17-1995	
		AK	5,545,723		Goelz et al.	08-13-1996	
V		AL	5,795,779		McCormick et al.	08-18-1998	

				FOREIGI	N PATENT DOCUMEN	TS		
Examin	Cite No.		Foreign Patent Docum			Date of Publication	Pages, Columns, Lines,	T
er Initials		Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T
उड	AM	wo	95/25170		Biogen, Inc.	09-21-1995	/	
	AN	WO	98/48018		Fraun-Hofer- Gesellschaft Zur Forderung Der Angewandten	10-29-1998		
	AO	wo	99/03887		Bolder Biotechnology	01-28-1999		
	AP	wo	99/55377		Applied Research	11-04-1999		
	AQ	wo	99/67291		Immunex Corporation	12-29-1999		
ول	AR	wo	00/23114		Biogen, Inc.	04-27-2000		

Examiner Signature	9 Della	Date Considered	9	27	107_
		00.10100.00	<u>—</u>		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.






Substitute for form 1449A-B/PTO Complete if Known **Application Number** 09/648,569 INFORMATION DISCLOSURE Filing Date August 25, 2000 STATEMENT BY APPLICANT First Named Inventor Anders, Hjelholt Pedersen 1633-1647 Group Art Unit **Examiner Name** Unassigned J. Senovaceyon (use as many sheets as necessary) Attorney Docket Number 31-107600US

-5	55	AS	wo	00/23472	Biogen, Inc.	04-27-2000	,
		AT	wo	00/26354	Novo Nordisk	05-11-2000	
		AU	EP	083 069	Kyowa Hakko Kogyo Co., Ltd.	09-16-1987	
		ΑV	EP	041 313	Biogen, Inc.	09-12-1990	
		AW	EP	229 108	Cetus Corporation	12-27-1990	
	\prod	AX	EP	260 350	Cetus Corporation	02-12-1992	
	•	AY	EP	287 075	Arzeneimittelforschung /Drug Research	01-18-1995	
7		AZ	EP	539 300	Philippe Thiriet	02-07-1996	
		ВА	EP	593 868	Hoffmann-La Roche Inc.	04-15-1998	

	· · · · · · · · · · · · · · · · · · ·	OTHER PRIOR ART - NON PATECNT LITERATURE DOCUMENTS	
Examin er Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
JS	ВВ	Fierlbeck et al., "Neutralising interferon β antibodies in melanoma patients treated with recombinant and natural interferon β" Cancer Immunol Immunother (1994) 39:263-268	
	ВС	Karpusas et al., "The Structure of Human Interferon- β: Implications for activity" <u>CMLS</u> 54 (1998) 1203-1216	
	BD	Karpusas <i>et al.</i> "The crystal structure of human interferon β at 2.2 A resolution" Proc. Nat. Acad. Sci. USA (1997) 94:11813-11818	
	BE	Mayorga et al., "Antibodies to Commercially Available Interferon-Bet Molecules in Multipule Sclerosis Patients Treated with Natural Interferon-Beta" Int. Arch. Allery Immunol 1999; 118:368-371	
	BF	Munschauer et al., "Managing Side Effects of Interferon-Beta in Patients with Relapsing-Remitting Multipule Sclerosis" Clinical Therapeutics vol. 19, No. 5, 1997 883-893	
V	BG	Redlich et al., "Antibodies that neutralize human β interferon biologic activity recognizing a linear epitope: Analysis by synthetic peptide mapping" Proc. Natl. Acad. Sci. USA vol. 88, pp. 4040-4044 May 1991	

Examiner Signature	Date Considered	9/27/02

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




Substitute for form 1449A-B/PTO	Complete if Known		
	Application Number	09/648,569	
INFORMATION DISCLOSURE	Filing Date	August 25, 2000	
STATEMENT BY APPLICANT	First Named Inventor	Anders, Hjelholt Pedersen	
;	Group Art Unit	1633-1647	
()	Examiner Name	Ginassigned J. Schare Seyon.	
(use as many sheets as necessary)	Attorney Docket Number	31-107600US	

-50	3 E	3H	Rudick et al., "Incidence and significance of neutralizing antibodies to interferon beta-1a in multipule sclerosis" Neurology May 1889, 50: 1266-1272
	Ε	31	Runkel et al., "Structural and Functional Differences Between Glycosylated and Non-Glycosylated Forms of Human Interferon- β (IFN- β) Pharmaceutical Research vol. 15, No 4, 1998, 641-649
	E	3J	Runkel et al, 1998, Jour. Biol. Chem. Difference in Activity between α and β Type I Interferons Explored by Mutational Analysis" 273, No. 14, pp. 8003-8008
	E	3K	Senda et al., "Refined Crystal Structure of Recombinant Murine Interferon- β at 2.15 A Resolution" J. Mil. Biol. (1995) 253, 187-207
	Е	3L	Stewart et al, DNA "Chemical Mutagenesis of Human Interferon- \(\beta \): Construction, Expression in E. coli, and Biological Activity of Sodium Bisulfite-Induced Mutations Vol 6 no 2 1987 p119-128
	В	ВМ	Tanigunchi, et al., "The nucleotide sequence of human fibroblast interferon cDNA" Gene 10 (1980) 11-15
4	В	BN	Yong et al., "Interferon beta in the treatment of multiple sclerosis" Neurology 1998; 51: 682-689

	$\overline{}$		<u>. </u>						
Examiner	10x	$\setminus 0$		<u> </u>	Date	a. /	0.0		
Signature	\bigcup \bigcup	Jer (-	Considered	-(27	102	
			\						

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449A-B/PTO	С	omplete if Known	
	Application Number	09/648,569	
INFORMATION DISCLOSURE	Filing Date	August 25, 2000	
STATEMENT BY APPLICANT	First Named Inventor	A. H. Pedersen	
	Group Art Unit	1647	9 6
	Examiner Name	J. Seharaseyon	N T
(use as many sheets as necessary)	Attorney Docket Number	0202us810	<u> </u>

			U.	S. PATENT DOCUMENTS		O RM
		U.S. Patent De	ocument	Name of Patentee or Applicant of	Date of Publication of	Pages, Columns, lines, <
Examiner Initials	Cite No.	Number	Kind Code (if known)	Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appeal
JS	1	5,206,344		Katre et al.	04/27/1993	2:3
8)	2	5,738,846		Greenwald et al.	04/14/1998	4

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Office	Foreign Patent Docur	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	т
35	3	EP	0 370 205	A2	Kyowa Hakko Kogyo Co., Ltd.	05/30/1990		
	4	EP	0 529 300	B1	Rentschler Biotechnologie GmbH & Co.	03/03/93		X
	5	EP	0 529 300 (English language translation of document #4)	B1	Rentschler Biotechnologie GmbH & Co.	03/03/93		
	6	wo	95/27502	A1	Research Develop- ment Foundation	10/19/1995		
	7	wo	98/35026	A1	Novo Nordisk A/S	08/13/1998		
4	8	wo	99/55377	A2	Applied Research Systems	11/04/1999		

		OTHER ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
-88	9	Derwent Abstract 012152872 for WO 98/48018, a German publication cited in previous IDS Form-1449.	
	10-	Derwent Abstract 009442954 for EP 539 300, a French publication cited in previous IDS Form-1449.	

		<u> </u>		
Examiner Signature	Ċ	1255	 Date Considered	9/27/07-
Olginature	`		Considered	
	_			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.